NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

HORA-PDE6B:新興醫藥品的考察、市場預測 (2030年)

HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959712
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
HORA-PDE6B:新興醫藥品的考察、市場預測 (2030年) HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

HORA-PDE6B是重組腺相關病毒(rAAV)載體,開發用於治療由於PDE6B基因突變引起的色素性視網膜炎。這種基因替代療法提供了人類PDE6B基因的未突變拷貝來替代有缺陷的基因,以誘導桿外部片段中功能性PDE6B蛋白的表現。HORA-PDE6B以病毒顆粒的無菌懸浮液形式給藥,直接注入視網膜下腔。這會觸發轉基因在視桿(表現PDE6B亞基的位置)以及視錐細胞中的表現。

本報告提供美國,歐洲5個國家(德國,法國,義大利,西班牙,英國)以及日本的7個主要市場上 HORA-PDE6B 詳細說明 (含作用機制,劑量,合成途徑,法規的里程碑的研究開發活動,及其他的開發活動),含SWOT分析,市場競爭企業,及其他新治療方法的未來市場評估。

目錄

第1章 醫藥品概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭企業

第6章 其他的新治療方法

第7章 附錄

第8章 報告購買選擇

目錄
Product Code: DIDM0063

"HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Retinitis pigmentosa in 7 Major Markets. A detailed picture of the HORA-PDE6B in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

HORA-PDE6B is a recombinant adeno-associated viral (rAAV) vector developed for the treatment of retinitis pigmentosa due to a mutation in the PDE6B gene. This gene replacement therapy provides an unmutated copy of the human PDE6B gene to replace the defective gene, in order to induce the expression of a functional PDE6B protein in the rod outer segment. HORA-PDE6B is administered as a sterile suspension of viral particles, injected directly into the subretinal space. This triggers the expression of the transgene in the rods (where the PDE6B subunit is expressed) as well as in the cones.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around HORA-PDE6B.
  • The report contains forecasted sales for HORA-PDE6B till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Retinitis pigmentosa.
  • The report also features the SWOT analysis with analyst insights and key findings of HORA-PDE6B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HORA-PDE6B Analytical Perspective by DelveInsight

  • In-depth HORA-PDE6B Market Assessment

This report provides a detailed market assessment of HORA-PDE6B in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • HORA-PDE6B Clinical Assessment

The report provides the clinical trials information of HORA-PDE6B covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Retinitis pigmentosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HORA-PDE6B dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Retinitis pigmentosa are giving market competition to HORA-PDE6B and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of HORA-PDE6B.
  • Our in-depth analysis of the forecasted sales data of HORA-PDE6B from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HORA-PDE6B.

Key Questions:

  • Which company is developing HORA-PDE6B along with the phase of the clinical study?
  • What is the technology utilized in the development of HORA-PDE6B?
  • What is the product type, route of administration and mechanism of action of HORA-PDE6B?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HORA-PDE6B development?
  • What are the key designations that have been granted to HORA-PDE6B?
  • What is the forecasted market scenario of HORA-PDE6B?
  • What is the history of HORA-PDE6B and what is its future?
  • What is the forecasted sales of HORA-PDE6B in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to HORA-PDE6B?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 HORA-PDE6B, Description
  • Table 2 HORA-PDE6B, Clinical Trial Description
  • Table 3 HORA-PDE6B, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of HORA-PDE6B
  • Figure 2 Patent Details, HORA-PDE6B
  • Figure 3 HORA-PDE6B, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 HORA-PDE6B, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 HORA-PDE6B, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 HORA-PDE6B, Japan Market Size from 2020 to 2030 (in Millions USD)